Molecular pathology of endometrial carcinoma: Practical aspects from the diagnostic and therapeutic viewpoints

Journal of Clinical Pathology

Volumn 62, Issue 9, 2009, Pages 777-785

  Llobet, D ^a   Pallares, J ^a   Yeramian, A ^a   Santacana, M ^a   Eritja, N ^a   Velasco, A ^a   Dolcet, X ^a   Matias Guiu, X ^a  

^a HOSPITAL UNIVERSITARI ARNAU DE VILANOVA   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

AURORA A KINASE; BETA CATENIN; BORTEZOMIB; DEFOROLIMUS; EPIDERMAL GROWTH FACTOR RECEPTOR 2; EVEROLIMUS; GEFITINIB; GESTAGEN; GOG 229C; HISTONE DEACETYLASE INHIBITOR; K RAS PROTEIN; LAPATINIB; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; PIK3CA PROTEIN; PROTEASOME INHIBITOR; PROTEIN; PROTEIN P16; PROTEIN P53; RAPAMYCIN; RAPAMYCIN DERIVATIVE; SORAFENIB; TEMSIROLIMUS; TRASTUZUMAB; UNCLASSIFIED DRUG; UVOMORULIN;

APOPTOSIS; CLINICAL TRIAL; COLON CANCER; DRUG MECHANISM; ENDOMETRIUM CARCINOMA; GENE MUTATION; HETEROZYGOSITY LOSS; HUMAN; MICROSATELLITE INSTABILITY; PATHOLOGY; PRIORITY JOURNAL; PROGNOSIS; REVIEW;

APOPTOSIS; ENDOMETRIAL NEOPLASMS; FEMALE; GENE THERAPY; HUMANS; MICROSATELLITE INSTABILITY; MUTATION; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS;

EID: 70349140898     PISSN: 00219746     EISSN: 14724146     Source Type: Journal    
DOI: 10.1136/jcp.2008.056101     Document Type: Review

References (65)

1. Bockman JV. Two pathogenetic types of endometrial carcinoma. Gynecol Oncol 1983;15:10-17
2. Lax SF, Kurman RJ. A dualistic model for endometrial carcinogenesis based on immunohistochemical and molecular genetic analyses. Verh Dtsch Ges Path 1997;81:228-232
3. Matias-Guiu X, Catasus L, Bussaglia E, et al. Molecular pathology of endometrial hyperplasia and carcinoma. Hum Pathol 2001;32:569-577 (Pubitemid 32601237)
4. Caduff RF, Johnston CM, Svoboda-Newman SM, et al. Clinical and pathological significance of microsatellite instability in sporadic endometrial carcinoma. Am J Pathol 1996;148:1671-1678 (Pubitemid 26135906)
5. Duggan BD, Felix JC, Muderspach LI, et al. Microsatellite instability in sporadic endometrial carcinoma. J Natl Cancer Inst 1994;86:1216-1221 (Pubitemid 24253696)
6. Kobayashi K, Sagae S, Kudo H, et al. Microsatellite instability in endometrial carcinomas: frequent replication errors in tumors of early onset and/or of poorly differentiated type. Genes Chromosom Cancer 1995;14:128-132
7. Risinger JI, Berchuck A, Kohler MF, et al. Genetic instability of microsatellites in endometrial carcinoma. Cancer Res 1993;53:5100-5103 (Pubitemid 23333372)
8. Catasús LI, Machin P, Matias-Guiu X, et al. Microsatellite instability in endometrial carcinomas clinicopathologic correlations in a series of 42 cases. Hum Pathol 1998;29:1160-1164 (Pubitemid 28467540)
9. Esteller M, Levine R, Baylin SB, et al. MLH1 promoter hypermethylation is associated with the microsatellite instability phenotype in sporadic endometrial carcinomas. Oncogene 1998;17:2413-2417 (Pubitemid 28515395)
10. Esteller M, Catasus LI, Matias-Guiu X, et al. hMLH1 promoter hypermethylation is an early event in human endometrial tumorigenesis. Am J Pathol 1999;155:1767-1772
11. Gurin ChC, Federici MG, Kang L, et al. Causes and consequences of microsatellite instability in endometrial carcinoma. Cancer Res 1999;59:462-466 (Pubitemid 29048884)
12. Sakamoto T, Murase T, Urushibata H, et al. Microsatellite instability and somatic mutations in endometrial carcinomas. Gynecol Oncol 1998;71:53-58 (Pubitemid 28492393)
13. Basil JB, Goodfellow PJ, Rader JS, et al. Clinical significance of microsatellite instability in endometrial carcinoma. Cancer 2000;89:1758-1764 (Pubitemid 30794170)
14. Gryfe R, Kim H, Hsieh ET, et al. Tumor microsatellite instability and clinical outcome in young patients with colorectal cancer. N Engl J Med 2000;342:69-77. (Pubitemid 30036597)
15. Catasus LI, Matias-Guiu X, Machin P, et al. BAX somatic framshift mutations in endometrioid adenocarcinomas of the endometrium: evidence for a tumor progression role in endometrioid carcinomas with microsatellite instability. Lab Invest 1998;78:1439-1444 (Pubitemid 28546087)
16. Catasus LI, Matias-Guiu X, Machin P, et al. Frameshift mutations at coding mononucleotide repeat microsatellites in endometrial carcinomas with microsatellite instability. Cancer 2000;88:2290-2297 (Pubitemid 30247129)
17. Mutter GL, Lin MC, Fitzgerald JT, et al. Altered PTEN expression as a diagnostic marker for the earliest endometrial precancers. J Natl Cancer Inst 2000;92:924-931
18. Terakawa N, Kanamori Y, Yoshida S. Loss of PTEN expression followed by Akt phosphorylation is a poor prognostic factor for patients with endometrial cancer. Endocr Relat Cancer 2003;10:203-208 (Pubitemid 36758649)
19. Salvesen HB, Stefansson I, Kalvenes MB, et al. Loss of PTEN expression is associated with metastatic disease in patients with endometrial carcinoma. Cancer 2002;94:2185-2191 (Pubitemid 34411976)
20. Kanamori Y, Kigawa J, Itamochi H, et al. PTEN expression is associated with prognosis for patients with advanced endometrial carcinoma undergoing postoperative chemotherapy. Int J Cancer 2002;100:686-689 (Pubitemid 34832979)
21. Bussaglia E, del Rio E, Matias-Guiu X, et al. PTEN mutations in endometrial carcinomas. A molecular and clinicopathologic analysis of 38 cases. Hum Pathol 2000;31:312-317
22. Tashiro H, Blazes MS, Wu R, et al. Mutations in PTEN are frequent in endometrial carcinoma but rare in other common gynecological malignancies. Cancer Res 1997;57:3935-3940 (Pubitemid 27427679)
23. Kong D, Suzuki A, Zou TT, et al. PTEN1 is frequently mutated in primary endometrial carcinomas. Nat Genet 1997;17:143-144
24. Risinger JI, Hayes AK, Berchuck A, et al. PTEN/MMAC1 mutations in endometrial cancers. Cancer Res 1997;57:4736-4738
25. Levine RL, Cargile CB, Blazes MS, et al. PTEN mutations and microsatellite instability in complex atypical hyperplasia, a precursor lesion to uterine endometrioid carcinoma. Cancer Res 1998;58:3254-3258
26. Oda K, Stokoe D, Taketani Y, et al. High frequency of coexistent mutations of PIK3CA and PTEN genes in endometrial carcinoma. Cancer Res 2005;65:10669-10673 (Pubitemid 41713332)
27. Velasco A, Bussaglia E, Pallares J, et al. PIK3CA gene mutations in endometrial carcinoma: correlation with PTEN and K-RAS alterations. Hum Pathol 2006;37:1465-1472 (Pubitemid 44584324)
28. Hayes MP, Wang H, Espinal-Witter R, et al. PIK3CA and PTEN mutations in uterine endometrioid carcinoma and complex atypical hyperplasia. Clin Cancer Res 2006;12:5932-5935 (Pubitemid 44703751)
29. Catasus L, Gallardo A, Cuatrecasas M, et al. PIK3CA mutations in the kinase domain (exon 20) of uterine endometrial adenocarcinomas are associated with adverse prognostic parameters. Mod Pathol 2008;21:131-139 (Pubitemid 351172164)
30. Swisher EM, Peiffer-Scheider S, Mutch DG, et al. Differences in patterns of TP53 and KRAS2 mutations in a large series of endometrial carcinomas with or without microsatellite instability. Cancer 1999;85:119-126
31. Lagarda H, Catasus LI, Argüelles R, et al. K-ras mutations in endometrial carcinoma with microsatellite instability. J Pathol 2001;193:193-199 (Pubitemid 32118131)
32. Pallarés J, Velasco A, Eritja N, et al. Promoter hypermethylation and reduced expression of RASSF1A are frequent molecular alterations of endometrial carcinoma. Mod Pathol 2008;21:691-699 (Pubitemid 351744834)
33. Fukuchi T, Sakamoto M, Tsuda, et al. Beta-catenin mutations in carcinoma of the uterine endometrium. Cancer Res 1998;58:3526-3528 (Pubitemid 28376543)
34. Kobayashi K, Sagae S, Nishioka Y, et al. Mutations of the beta-catenin gene in endometrial carcinomas. Jpn J Cancer Res 1999;90:55-59 (Pubitemid 29084311)
35. Mirabelli-Primdahl L, Gryfe R, Kim H, et al. Beta-catenin mutations are specific for colorectal carcinomas with microsatellite instability but occur in endometrial carcinomas irrespective of mutator pathway. Cancer Res 1999;59:3346-3351 (Pubitemid 29334489)
36. Schlosshauer PW, Pirog EC, Levine RL, et al. Mutational analysis of the CTNNB1 and APC genes in uterine endometrioid carcinoma. Mod Pathol 2000;13:1066-1071
37. Machin P, Catasus L, Pons C, et al. CTNNB1 mutations and beta-catenin expression in endometrial carcinomas. Hum Pathol 2002;33:206-212 (Pubitemid 34298736)
38. Moreno-Bueno G, Hardisson D, Sánchez C, et al. Abnormalities of the APC/beta-catenin pathway in endometrial cancer. Oncogene 2002;14:7981-7990 (Pubitemid 35430609)
39. Tashiro H, Isacson C, Levine R, et al. p53 gene mutations are common in uterine serous carcinoma and occurs early in their pathogenesis. Am J Pathol 1997;150:177-185 (Pubitemid 27027108)
40. Sherman ME, Bur ME, Kurman RJ. p53 in endometrial cancer and its putative precursors: evidence for diverse pathways of tumorigenesis. Hum Pathol 1995;26:1268-1274
41. Egan JA, Ionescu MC, Eapen E, et al. Differential expression of WT1 and p53 in serous and endometrioid carcinomas of the endometrium. Int J Gynecol Pathol 2004;23:119-122 (Pubitemid 38391770)
42. Alkushi A, Lim P, Coldman A, et al. Interpretation of p53 immunoreactivity in endometrial carcinoma: establishing a clinically relevant cut-off level. Int J Gynecol Pathol 2004;23:129-137 (Pubitemid 38391772)
43. Moreno-Bueno G, Hardisson D, Sarrió D, et al. Abnormalities of E- and P-cadherin and catenin (beta-, gamma-catenin, and p120ctn) expression in endometrial cancer and endometrial atypical hyperplasia. J Pathol 2003;1999:471-478 (Pubitemid 36411224)
44. Morrison C, Zanagnolo V, Ramirez N, et al. HER-2 is an independent prognostic factor in endometrial cancer: association with outcome in a large cohort of surgically staged patients. J Clin Oncol 2006;24:2376-2385 (Pubitemid 46630670)
45. Tritz D, Pieretti M, Turner S, et al. Loss of heterozygosity in usual and special variant carcinomas of the endometrium, Hum Pathol 1997;28:607-612 (Pubitemid 27213058)
46. Pallares J, Martinez-Guitarte JL, Dolcet X, et al. Abnormalities in NF-kB family and related proteins in endometrial carcinoma. A tissue microarray study. J Pathol 2004;13:569-577 (Pubitemid 39585956)
47. Pallares J, Martínez-Guitarte JL, Dolcet X, et al. Survivin expression in endometrial carcinoma: a tissue microarray study with correlation with PTEN and STAT-3. Int J Gynecol Pathol 2005;24:247-253 (Pubitemid 40885078)
48. Dolcet X, Llobet D, Pallares J, et al. FLIP is frequently expressed in endometrial carcinoma and has a role in resistance to TRAIL-induced apoptosis. Lab Invest 2005;85:885-894 (Pubitemid 41021297)
49. Llobet D, Eritja N, Encinas M, et al. CK2 controls TRAIL and Fas sensitivity by regulating FLIP levels in endometrial carcinoma cells. Oncogene 2008;27:2513-2524 (Pubitemid 351550887)
50. Moreno-Bueno G, Sánchez-Estévez C, Cassia R, et al. Differential gene expression profile in endometrioid and nonendometrioid endometrial carcinoma: STK15 is frequently overexpressed and amplified in nonendometrioid carcinomas. Cancer Res 2003;63:5697-5702 (Pubitemid 37187463)
51. Risinger JI, Maxwell GL, Chandramouli GV, et al. Microarray analysis reveals distinct gene expression profiles among different histologic types of endometrial cancer. Cancer Res 2003;63:6-11.
52. Maxwell GL, Chandramouli GV, Dainty L, et al. Microarray analysis of endometrial carcinomas and mixed mullerian tumors reveals distinct gene expression profiles associated with different histologic types of uterine cancer. Clin Cancer Res 2005;11:4056-4066 (Pubitemid 40791569)
53. Cao QJ, Belbin T, Socci N, et al. Distinctive gene expression profiles by cDNA microarrays in endometrioid and serous carcinomas of the endometrium. Int J Gynecol Pathol 2004;23:321-329 (Pubitemid 39299020)
54. Risinger JI, Maxwell GL, Chandramouli GV, et al. Gene expression profiling of microsatellite unstable and microsatellite stable endometrial cancers indicates distinct pathways of aberrant signaling. Cancer Res 2005;65:5031-5037
55. Shedden KA, Kshirsagar MP, Schwartz DR, et al. Histologic type, organ of origin, and Wnt pathway status: effect on gene expression in ovarian and uterine carcinomas. Clin Cancer Res 2005;11:2123-2131
56. Planagumà J, Díaz-Fuertes M, Gil-Moreno A, et al. A differential gene expression profile reveals overexpression of RUNX1/AML1 in invasive endometrioid carcinoma. Cancer Res 2004;64:8846-8853 (Pubitemid 39665488)
57. Zorn KK, Bonome T, Gangi L, et al. Gene expression profiles of serous, endometrioid, and clear cell subtypes of ovarian and endometrial cancer. Clin Cancer Res 2005;11:6422-6430 (Pubitemid 41338978)
58. Chon HS, Hu W, Kavanagh JJ. Targeted therapies in gynecologic cancers. Curr Cancer Drug Targets 2006;6:333-363
59. Podsypanina K, Lee RT, Politis C, et al. An inhibitor of mTOR reduces neoplasia and normalizes p70/S6 kinase activity in Pten+/- mice. Proc Natl Acad Sci USA 2001;28:10320-10325 (Pubitemid 32803018)
60. Dolcet X, Llobet D, Encinas M, et al. Proteasome inhibitors induce death but activate NF-kappaB on endometrial carcinoma cell lines and primary culture explants. J Biol Chem 2006;281:22118-22130 (Pubitemid 44181916)
61. Llobet D, Eritja N, Encinas M, et al. Antioxidants block proteasome inhibitor function in endometrial carcinoma cells. Anticancer Drugs 2008;19:115-124
62. Gunin AG, Kapitova IN, Suslonova NV. Effects of histone deacetylase inhibitors on estradiol-induced proliferation and hyperplasia formation in the mouse uterus. J Endocrinol 2005;185:539-549
63. Takai N, Desmond JC, Kumagai T, et al. Histone deacetylase inhibitors have a profound antigrowth activity in endometrial cancer cells. Clin Cancer Res 2004;10:1141-1149 (Pubitemid 38198916)
64. Pallares J, Bussaglia E, Martínez-Guitarte JL, et al. Immunohistochemical analysis of PTEN in endometrial carcinoma: a tissue microarray study with a comparison of four commercial antibodies in correlation with molecular abnormalities. Mod Pathol 2005;18:719-727 (Pubitemid 40676385)
65. Irving JA, Catasús L, Gallardo A, et al. Synchronous endometrioid carcinomas of the uterine corpus and ovary: alterations in the beta-catenin (CTNNB1) pathway are associated with independent primary tumors and favorable prognosis. Hum Pathol 2005;36:605-619 (Pubitemid 40922566)